Anti-CTLA-8/IL-17a Antibody (Secukinumab)
Catalog No.
F1242
Anti-CTLA-8/IL-17a Antibody (Secukinumab)
Featured Products
Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent being investigated in plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
147.82 kDa
Dry ice
1229022-83-6
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Cosentyx, AIN457
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q16552
Human, Cynomolgus, Rhesus
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human IL 17A FC at 2 ug/mL can bind Anti-CTLA-8/IL-17a Antibody (Secukinumab)
CTLA-8 / IL-17a
Please avoid freeze-thaw cycles.